目的 探討特布他林聯(lián)合復(fù)方甲氧那明膠囊治療咳嗽變異性哮喘的臨床療效。方法 選取2016年1月-2017年1月在首都醫(yī)科大學(xué)宣武醫(yī)院治療的咳嗽變異性哮喘患者86例，根據(jù)治療方案的差別分為對照組（43例）和治療組（43例）。對照組患者口服復(fù)方甲氧那明膠囊，2粒/次，3次/d。治療組在對照組基礎(chǔ)上霧化吸入硫酸特布他林霧化液，5 mg/次加入生理鹽水2 mL，3次/d。兩組患者均治療4周。評價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者臨床癥狀評分、肺功能和血清學(xué)指標(biāo)。結(jié)果 治療后，對照組患者總有效率為79.07%，顯著低于治療組的95.35%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者慢性咳嗽、咳痰、咽癢和喘息急促等臨床癥狀積分均顯著降低（P<0.05）；且治療組臨床癥狀評分比對照組更低（P<0.05）。治療后，兩組患者第一秒用力呼氣容積（FEV1）、用力肺活量（FVC）、最大呼氣流量（PEF）均顯著增高（P<0.05）；且治療組患者肺功能明顯好于對照組（P<0.05）。治療后，兩組患者血清白細(xì)胞介素-4（IL-4）、腫瘤壞死因子-α（TNF-α）和降鈣素原（PET）水平顯著降低，白細(xì)胞介素-10（IL-10）和干擾素-γ（IFN-γ）水平顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述指標(biāo)變化明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 特布他林聯(lián)合復(fù)方甲氧那明膠囊治療咳嗽變異性哮喘不僅能夠有效改善臨床癥狀和肺功能，還可改善血清相關(guān)炎性因子水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of terbutaline combined with Compound Methoxyphenamine Capsules in treatment of cough variant asthma. Methods Patients (86 cases) with cough variant asthma in Xuanwu Hospital Capital Medical University from January 2016 to January 2017 were divided into control (43 cases) and treatment (43 cases) groups according to different treatments. Patients in the control group were po administered with Compoumd Methoxyphenamine Hydrochloride Capsules, 2 grains/time, three times daily. Patients in the treatment group were aerosol inhalation administered with Terbutaline Sulphate Solution for nebulization on the basis of the control group, 5 mg added into normal saline 2 mL, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom scores, pulmonary function, and serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 79.07%, which was significantly lower than 95.35% in the treatment group, and the difference was statistically significant between two groups (P<0.05). After treatment, the chronic cough, expectoration, pharyngeal itching and shortness of breath scores in two groups was significantly decreased (P<0.05). And the clinical symptom scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the FEV₁, FVC and PEF in two groups were significantly increased (P<0.05). And the pulmonary function in the treatment group was obviously better than that in the control group (P<0.05). After treatment, the IL-4, TNF-α and PET level in two groups was significantly decreased, but IL-10 and IFN-γ level was significantly increased, and the difference was statistically significant in the same group (P<0.05). And the change of these indexes in the treatment group was obviously better than that in the control group, with significant difference between two groups (P<0.05). Conclusion Terbutaline combined with Compound Methoxyphenamine Capsules can effectively improve the clinical symptoms and pulmonary function in treatment of cough variant asthma, and improve serum inflammatory factor levels, which has a certain clinical application value.